TY - JOUR
T1 - A comparison and analysis of several ways to promote haematin (haem) polymerisation and an assessment of its initiation in vitro
AU - Dorn, Arnulf
AU - Vippagunta, Sudha Rani
AU - Matile, Hugues
AU - Bubendorf, André
AU - Vennerstrom, Jonathan L.
AU - Ridley, Robert G.
N1 - Funding Information:
This investigation received some financial support from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (to JLV).
PY - 1998/3/15
Y1 - 1998/3/15
N2 - We compared several methods for producing haematin polymerisation at physiological temperatures (i.e., 37°) and found that a trophozoite lysate- mediated reaction was inappropriate for measuring compound inhibition of haematin polymerisation. Using this method, we obtained significantly higher IC50 values (concentration inhibiting haematin polymerisation by 50%) for certain compounds than when other methods were used, including a food vacuole lysate-mediated reaction. This difference was probably due to the binding of these compounds to cytosolic parasite proteins, as proteinase K treatment of the trophozoite lysate reversed this effect. The initiation of haematin polymerisation was also investigated using several assays. It was found that haematin polymerisation occurred spontaneously, in the absence of preformed haemozoin, over a period of several days, but that the process was more rapid when an acetonitrile extract of malarial trophozoites was added. This extract contained no detectable protein, and its activity could be replicated using an extract from uninfected erythrocytes and by using lipids. We therefore postulate that no protein or parasite-specific material is absolutely required for the initiation of haematin polymerisation. The formation of β- haematin de novo using the acetonitrile extract is more pH-dependent than the generation of newly synthesised β-haematin from preformed haemozoin and cannot proceed much above pH = 6. We postulate that the initiation of haematin polymerisation is more sensitive to the equilibrium of haematin between its monomeric and μ-oxo dimer form and requires a higher concentration of monomer than for the elongation phase of polymerisation.
AB - We compared several methods for producing haematin polymerisation at physiological temperatures (i.e., 37°) and found that a trophozoite lysate- mediated reaction was inappropriate for measuring compound inhibition of haematin polymerisation. Using this method, we obtained significantly higher IC50 values (concentration inhibiting haematin polymerisation by 50%) for certain compounds than when other methods were used, including a food vacuole lysate-mediated reaction. This difference was probably due to the binding of these compounds to cytosolic parasite proteins, as proteinase K treatment of the trophozoite lysate reversed this effect. The initiation of haematin polymerisation was also investigated using several assays. It was found that haematin polymerisation occurred spontaneously, in the absence of preformed haemozoin, over a period of several days, but that the process was more rapid when an acetonitrile extract of malarial trophozoites was added. This extract contained no detectable protein, and its activity could be replicated using an extract from uninfected erythrocytes and by using lipids. We therefore postulate that no protein or parasite-specific material is absolutely required for the initiation of haematin polymerisation. The formation of β- haematin de novo using the acetonitrile extract is more pH-dependent than the generation of newly synthesised β-haematin from preformed haemozoin and cannot proceed much above pH = 6. We postulate that the initiation of haematin polymerisation is more sensitive to the equilibrium of haematin between its monomeric and μ-oxo dimer form and requires a higher concentration of monomer than for the elongation phase of polymerisation.
KW - Assay methodology
KW - Haematin polymerisation
KW - Initiation
KW - Malaria
KW - pH- dependence
KW - β-Haematin
UR - http://www.scopus.com/inward/record.url?scp=0032520711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032520711&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(97)00509-1
DO - 10.1016/S0006-2952(97)00509-1
M3 - Article
C2 - 9586945
AN - SCOPUS:0032520711
SN - 0006-2952
VL - 55
SP - 737
EP - 747
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 6
ER -